Download Laboratory Acquired Infections

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Leptospirosis wikipedia , lookup

Trichinosis wikipedia , lookup

Hepatitis B wikipedia , lookup

Eradication of infectious diseases wikipedia , lookup

Henipavirus wikipedia , lookup

Ebola virus disease wikipedia , lookup

United States biological defense program wikipedia , lookup

Herpes simplex virus wikipedia , lookup

Sexually transmitted infection wikipedia , lookup

West Nile fever wikipedia , lookup

African trypanosomiasis wikipedia , lookup

Middle East respiratory syndrome wikipedia , lookup

Brucellosis wikipedia , lookup

Marburg virus disease wikipedia , lookup

Chickenpox wikipedia , lookup

Pandemic wikipedia , lookup

Hospital-acquired infection wikipedia , lookup

Bioterrorism wikipedia , lookup

Lymphocytic choriomeningitis wikipedia , lookup

Transcript
1
Overview of
Laboratory Acquired Infections
Life Sciences Institute &
Singapore Institute for Clinical Sciences (Brenner Centre)
SAFETY DAY 2009
Copyright © 2009 by Limsoon Wong
Contact Info
Scott Patlovich, MPH, CBSP
Senior Safety & Health Manager
Office of Safety, Health, & Environment
Office: 6516 8802
[email protected]
Definition of LAI
• Laboratory acquired infection (LAI) = an
infection obtained through laboratory or
laboratory-related activities as a result of work
with infectious biological agents, which may
be either symptomatic of asymptomatic
History of LAIs
• Four hallmark studies by Pike and Sulkin
collectively identified 4,079 LAIs resulting in
168 deaths between 1930 – 1978
• 159 causative agents identified, although >50%
were caused by 10 most common organisms
• Many more LAIs likely unreported during this
time period
(1930-1978)
Source: Pike, 1976 & 1978
History of LAIs
• Harding and Byers literature search of LAIs for
20 years following Pike and Sulkin publications
found 1,267 overt infections with 22 deaths
• Harding and Byers also reported:
– <20% of LAIs from known exposure or documented
accident in the lab
– Only 7 documented secondary infections from LAIs
(1979 – 1999)
Despite Controls, LAIs Continue
• 1979 Pike concluded “the knowledge, the
techniques, and the equipment to prevent
most laboratory infections are available”
• Yet, laboratory acquired infections continue to
occur…(even today)
“The conventional wisdom is that laboratory-acquired infections are kept under
control by stringent CDC guidelines first introduced in 1984, at a time when
investigations of pathogenic bacteria were just starting to bloom. The reality is that
no one knows what the reality of laboratory-acquired infections is.”
Biosafety Guidelines & Regulations
• CDC/NIH. Biosafety in Microbiological and
Biomedical Laboratories, 5th Edition. (2007)
http://www.cdc.gov/OD/ohs/biosfty/bmbl5/bmbl5toc.htm
• World Health Organization. Laboratory Biosafety
Manual, 3rd Edition. (2004)
http://www.who.int/csr/resources/publications/biosafety/Biosafety7.pdf
• Ministry of Health Singapore. Biological Agents
and Toxins Act [BATA]. (2006)
http://www.biosafety.moh.gov.sg/bioe/ui/pages/links/abt_bata.htm
Biosafety Controls
• Practices, procedures, and facility controls
described in biosafety level criteria (BSLs)
• Risk grouping of infectious biological agents
• Emphasis on risk assessment, training, SOPs,
disinfection, waste management, immunization,
post-exposure prophylaxis, biosecurity, etc.
• LAIs are not exclusive to BSL-3 or BSL-4
laboratories – many occur in BSL-2 laboratories
Potential Routes of Transmission
• Inhalation – infectious aerosols, droplets
• Ingestion – mouth pipetting; eating, drinking
• Percutaneous inoculation – needlesticks and
other contaminated sharps; animal bites;
exposure to previously broken or damaged skin
• Mucous membrane exposure – infectious
materials in contact with eyes, nose, mouth
(splashes, contact from contaminated surfaces)
“Laboratory A” (2002)
Who: 1 unvaccinated worker at private lab (“laboratory A”) processing
environmental samples following October 2001 anthrax mailings
Agent: virulent Bacillus anthracis
Route of Exposure: Cutaneous
Source: Positive environmental sample not properly handled, plus
individual had pre-existing fresh cut on neck from shaving
Result: cutaneous anthrax disease including black eschar on neck
Other findings: 70% ethanol used for storage vials when 10% bleach
prescribed in SOPs; gloves not used to handle vials; wipe samples of
lab surfaces indicated only vials were possible source of
contamination
“Laboratory A” (2002)
Who: 1 unvaccinated worker at private lab (“laboratory A”) processing
environmental samples following October 2001 anthrax mailings
Agent: virulent Bacillus anthracis
Route of Exposure: Cutaneous
Source: Positive environmental sample not properly handled, plus
individual had pre-existing fresh cut on neck from shaving
Result: cutaneous anthrax disease including black eschar on neck
Other findings: 70% ethanol used for storage vials when 10% bleach
prescribed in SOPs; gloves not used to handle vials; wipe samples of
lab surfaces indicated only vials were possible source of
contamination
Boston University (2004)
Who: 3 researchers suspected with pneumonic tularemia
Agent: Live Vaccine Strain of Francisella tularensis (LVS stock contaminated
with wild-type (Type A) virulent form of organism)
Route of Exposure: Inhalation
Source: Undetermined; several procedures occurring during time period (i.e.
centrifuging, vortexing, colony counts not in a BSC)
OSHA fine: US$8100 (for improper use of PPE)
Other outcomes: City of Boston Public Health Department to survey lab; first
ever City of Boston IBC review panel to review all biomedical research in
city; construction of new BSL-4 labs highly controversial with public
Boston University (2004)
Who: 3 researchers suspected with pneumonic tularemia
Agent: Live Vaccine Strain of Francisella tularensis (LVS stock contaminated
with wild-type (Type A) virulent form of organism)
Route of Exposure: Inhalation
Source: Undetermined; several procedures occurring during time period (i.e.
centrifuging, vortexing, colony counts not in a BSC)
OSHA fine: US$8100 (for improper use of PPE)
Other outcomes: City of Boston Public Health Department to survey lab; first
ever City of Boston IBC review panel to review all biomedical research in
city; construction of new BSL-4 labs highly controversial with public
Science,
September
2007
Madison Chamber
Photo courtesy of Hillier Architecture
Texas A&M University (2007)
Who: 1 student worker infected in Brucella lab exposure incident
Agent: virulent Brucella spp.
Route of Exposure: Mucous membrane exposure (eyes)
Source: Improperly trained student worker entered Madison
containment chamber to clean unit after aerosolization procedure
CDC fine: US$1 million (plus lost grant dollars during lab shutdown)
Other outcomes: Failure to properly report cases resulted in cease &
desist order from CDC on all infectious disease lab work for nearly
one year; significant reputational damage to university
Texas A&M University (2007)
Who: 1 student worker infected in Brucella lab exposure incident
Agent: virulent Brucella spp.
Route of Exposure: Mucous membrane exposure (eyes)
Source: Improperly trained student worker entered Madison
containment chamber to clean unit after aerosolization procedure
CDC fine: US$1 million (plus lost grant dollars during lab shutdown)
Other outcomes: Failure to properly report cases resulted in cease &
desist order from CDC on all infectious disease lab work for nearly
one year; significant reputational damage to university
Vaccinia Virus (2007)
Who: 1 unvaccinated worker at a Virginia academic institution
Agent: Vaccinia Virus (live viral component of smallpox vaccine)
Route of Exposure: Unknown currently
Source: Recombinant stock likely to be contaminated with “Western
Reserve” strain of virus
Secondary Infections: 102 possible contacts identified; no secondary
infections occurred
Vaccinia Virus (2007)
Who: 1 unvaccinated worker at a Virginia academic institution
Agent: Vaccinia Virus (live viral component of smallpox vaccine)
Route of Exposure: Unknown currently
Source: Recombinant stock likely to be contaminated with “Western
Reserve” strain of virus
Secondary Infections: 102 possible contacts identified; no secondary
infections occurred
Recent Vaccinia LAI’s
Source: US Centers for Disease Control & Prevention
Emory University (1997)
Who: 1 worker at the Yerkes Regional Primate Research Center at Emory
University in Atlanta, Georgia engaged in behavioral research on hormonal
influences in Rhesus macaques
Agent: Cercopithecine Herpes Virus 1 (B-virus)
Route of Exposure: Mucous membrane exposure (right eye)
Source: Splash of bodily fluid from macaque to unprotected eyes (no safety
glasses/goggles worn at time of exposure)
Result: Fatality of 22-year old female (approx. 6 weeks following exposure)
Other findings: No report of exposure until after onset of symptoms of
disease; post-exposure treatment not adequate
Note: infected macaques are often asymptomatic (no lesions)
Emory University (1997)
Who: 1 worker at the Yerkes Regional Primate Research Center at Emory
University in Atlanta, Georgia engaged in behavioral research on hormonal
influences in Rhesus macaques
Agent: Cercopithecine Herpes Virus 1 (B-virus)
Route of Exposure: Mucous membrane exposure (right eye)
Source: Splash of bodily fluid from macaque to unprotected eyes (no safety
glasses/goggles worn at time of exposure)
Result: Fatality of 22-year old female (approx. 6 weeks following exposure)
Other findings: No report of exposure until after onset of symptoms of
disease; post-exposure treatment not adequate
Note: infected macaques are often asymptomatic (no lesions)
Other Infectious Disease Lab “Mishaps”
Texas Tech University
Who: Thomas Butler
Agent: Yersinia pestis
What: Apparent loss of 30 vials
containing bacteria
How Much: 69 counts including
illegal transportation, tax fraud,
embezzlement, fraud, lying to
federal officials
Outcomes: 2 years jail time &
US$38,000 fine
LAIs – Lessons Learned
• Prevention of LAIs can be achieved through:
– Risk assessment! Risk assessment! Risk assessment!
– Establishment of SOPs (controls) appropriate for
infectious organisms used
– Immunization, when available
– Education and training
– Use of appropriate precautions including engineering,
administrative, and PPE controls
– Understanding of disease signs & symptoms
– Prompt injury/accident/illness reporting
Thank You!